文献速递白血病造血干细胞移植与细胞治疗

急性髓系白血病缓解期患者卵巢组织可测量残留病的评估:一项初步研究

Assessment of measurable residual disease in ovarian tissue collected for fertility preservation in patients in remission from acute myeloid leukaemia: A pilot study.
PubMed 文献 · Br J Haematol · 2025-12-19

FERTILAM初步研究评估了9例接受卵巢组织冻存(OTC)的急性髓系白血病(AML)完全缓解(CR)患者在异基因造血干细胞移植(ASCT)前采集的卵巢组织中的可测量残留病(MRD)。采用患者特异性克隆标志物,通过微滴数字PCR检测骨髓、卵巢皮质和髓质的DNA和RNA。结果显示9例中4例卵巢皮质可检出MRD-DNA,且均伴骨髓MRD阳性,提示尽管达到CR,卵巢组织仍可能存在白血病细胞残留。

要点

  • AML完全缓解期卵巢组织可检出MRD-DNA,9例中4例卵巢皮质阳性。
  • 卵巢皮质MRD阳性者均伴骨髓MRD阳性,但3例骨髓和卵巢均阴性。
  • 卵巢组织移植前需高灵敏度分子检测评估安全性。

核心结论

  • AML患者达完全缓解后,卵巢组织仍可能残留白血病细胞,卵巢组织冻存移植前需敏感分子检测评估安全性。

研究设计与样本

  • FERTILAM初步研究纳入9例接受卵巢组织冻存(OTC)的AML完全缓解患者,在异基因造血干细胞移植前采集卵巢组织。
  • 采用患者特异性克隆标志物,通过微滴数字PCR检测骨髓、卵巢皮质和髓质DNA和RNA中的MRD。

主要发现

  • 9例中4例卵巢皮质检出MRD-DNA,且均同时存在骨髓MRD阳性。
  • 3例患者骨髓和卵巢组织MRD均为阴性。
  • 6例配对皮质/髓质分析中5例MRD-DNA结果一致。
  • 骨髓MRD-RNA与MRD-DNA完全一致;卵巢组织中MRD-DNA与MRD-RNA存在2处不一致。

临床怎么用

  • 对AML缓解期患者行卵巢组织冻存时,应检测卵巢组织MRD以评估移植后白血病复发风险。
  • 推荐采用高灵敏度分子方法(如微滴数字PCR)检测卵巢组织MRD。

局限性

  • 本研究为初步研究,样本量小(9例),结论需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic haematopoietic stem cell transplantation (ASCT) is a curative treatment for acute myeloid leukaemia (AML) but carries a high risk of gonadotoxicity. Ovarian tissue cryopreservation (OTC) offers a fertility preservation option, yet its safety in AML remains uncertain due to the risk of leukaemic cell reintroduction. The FERTILAM pilot study evaluated measurable residual disease (MRD) in ovarian tissue collected at complete remission (CR) from nine AML patients undergoing OTC before ASCT. MRD was assessed using patient-specific clonal markers via droplet digital polymerase chain reaction on DNA and RNA from bone marrow (BM), ovarian cortex and medulla. At CR, MRD-DNA was detected in ovarian cortex of four of nine patients, all with concurrent MRD positivity in BM. Three patients were negative in both BM and ovarian tissue. Paired cortex/medulla analyses showed concordant MRD-DNA results in five of six patients. BM MRD-RNA and MRD-DNA were fully concordant, whereas two discrepancies were observed between MRD-DNA and MRD-RNA in ovarian tissue. These findings suggest potential leukaemic cell persistence in ovarian tissue despite CR and highlight the need for sensitive molecular assays to assess safety prior to ovarian tissue transplantation.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Boudry A, Chevillon F, Marceau-Renaut A, et al. Assessment of measurable residual disease in ovarian tissue collected for fertility preservation in patients in remission from acute myeloid leukaemia: A pilot study. Br J Haematol. 2025. PMID: 41416831. doi:10.1111/bjh.70289

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。